Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.
Data Continue to Illustrate Potential Role of Partial Breast Irradiation in Early-Stage Breast Cancer
Revisit the OncLive On Air Episodes From February 2024
FDA Approves Lumisight and Lumicell DVS for Residual Breast Cancer Detection
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
Examining the Evolution of Treatment With CDK4/6 Inhibitors in Metastatic Breast Cancer
FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma